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STRUCTURED SUMMARY   
Objective 
The aim of this study is to look at the influence of metformin intake and duration, on urinary 
bladder cancer (UBC) risk, with sulfonylurea (SU) only users as control using a new-user 
design (inception cohort). 
Methods 
We conducted a retrospective cohort study using data from the UK Clinical Practice Research 
Datalink (CPRD) including all patients with at least one prescription of oral anti-diabetic 
drugs (ADD) and/or insulin. The risk of UBC in different groups of ADD users (metformin 
alone (1), metformin in combination (2) with other ADD medication (glinides, glitazones, 
DPP-4-inhibitors, SUs, insulin or more than one combination), all metformin users (1 + 2) 
was compared with SU only users using Cox proportional hazards models. The estimates 
were adjusted for age, gender, smoking status, BMI and diabetes duration.  
Results 
The inception cohort included 165,398 participants of which 132,960 metformin users and 
32,438 SU only users. During a mean follow-up time of more than five years 693 patients 
developed UBC, 124 of the control group and 461 of the all metformin users. There was no 
association between metformin use and UBC risk (HR = 1.12 (95% CI 0.90-1.40)) compared 
to SU only users, even after adjustment for diabetes duration (HR = 1.13 (95% CI 0.90-
1.40)). We found a pattern of decreasing risk of UBC with increasing duration of metformin 
intake, which was statistically not significant.  
 
Conclusion 
Metformin has no influence on the risk of UBC compared to SU in type 2 diabetes patients 
using a new-user design.  
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What is already known about this subject? 
 Epidemiological studies suggest a protective effect of metformin on cancer. 
 A meta-analysis of clinical trials could not confirm this protective effect. 
 Metformin inhibits the growth of bladder cancer cells in vitro and in vivo and may 
diminish recurrence and progression of non-invasive bladder cancer and recurrence 
and mortality after radical cystectomy. 
What this study adds? 
 Metformin has no protective effect on the risk of bladder cancer. 
 This study confirms the importance to use data from incident users in 
pharmacological epidemiology in order to eliminate time related bias and to obtain 
reliable results. 
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Introduction 
In 2014, in the United Kingdom (UK) 5.4% of the population was a diabetes patient while 
worldwide, diabetes mellitus affected 387 million adults (aged 20–79 years) causing nearly 5 
million deaths [1]. In 2012, more than 400,000 bladder cancer (UBC) cases occurred 
worldwide, making it the 7
th
 most common type of cancer [2]. Although most cohort and 
case-control studies demonstrated an increased risk of UBC due to type 2 diabetes compared 
to non-diabetic controls with a relative risk (RR) ranging from 1.11 (95% CI 1.00-1.23) to 
1.32 (95% CI 1.18–1.49) adjusted for smokers [3-5], neither the risk of UBC nor the 
mortality from UBC was increased in patients with type 1 and patients with type 2 diabetes in 
the UK Clinical Practice Research Datalink (CPRD) with a hazard ratio (HR) of 0.77 (95% 
CI 0.57-1.05) and 1.04 (95% CI 0.96-1.14) for type 1 and 2 diabetes, respectively [6]. The 
influence of different anti-diabetic drugs (ADD), especially metformin, on the risk of UBC is 
still unclear. The reduction of circulating level of insulin and insulin-like growth factor 1 
(IGF-1) by metformin might be associated with anticancer action. Insulin/IGF-1 is involved 
not only in regulation of glucose uptake but also in carcinogenesis through up-regulation of 
insulin/IGF receptor signalling pathway. Furthermore, metformin is thought to inhibit the 
mammalian target of rapamycin (mTOR) pathway, which plays a pivotal role in metabolism, 
growth and proliferation of cancer cell. [7] Currently, metformin as an anti-cancer drug, is 
under investigation in 199 clinical trials [8]. Metformin, as well as sulfonylurea (SU), are 
used as a first line treatment for type 2 diabetes and both are used in mono-therapy in early 
stage of type 2 diabetes [9, 10]. Epidemiological evidence suggests that metformin reduces 
the risk of cancer [11-14], including bladder cancer [15] and cancer-related mortality [16, 
17]. Metformin inhibits the growth of bladder cancer cells in vitro and in vivo [18, 19] and 
may diminish recurrence and progression of non-invasive bladder cancer and recurrence and 
mortality after radical cystectomy [20, 21]. However, epidemiological studies were likely 
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subject to confounding by indication and were not designed to differentiate between the 
effect of the drug from that of the underlying disease. A recent meta-analysis of randomised 
clinical trials (RCT) evaluating cancer outcome in patients using metformin did not confirm 
the hypothesis that metformin lowers cancer risk [22]. RCTs were less subject to time-related 
bias than observational studies. Time-related biases [23] include immortal time bias, a bias 
introduced with time-fixed cohort analyses that misclassify unexposed time as exposed as is 
the case in the study from Bowker et al.[17]; time-window bias, a bias introduced because of 
differential exposure opportunity time windows between subjects as is the case in the study 
from Ngwana et al.[14]; and time-lag bias, a bias introduced by comparing treatments given 
at different stages of the disease as in the study from Libby et al.[13]. Analysing patients 
according to time since the start of the medication under surveillance using a new-user design 
[24] or inception cohort, prevents time-related bias and brings the results fall in line with the 
results from clinical trials [25].  
We examined the influence of metformin intake, including duration, on UBC risk, with SU 
only users as control using a new-user design (inception cohort). 
 
METHODS 
Data sources 
We conducted a retrospective cohort study using data from the UK Clinical Practice Research 
Datalink (CPRD) (January 1987-October 2013). The CPRD comprises prospectively 
collected computerized medical records of over 10 million patients under the care of more 
than 600 general practitioners (GPs) in the United Kingdom (UK). The Read classification 
[26] is used to enter medical diagnoses and procedures, and prescriptions are recorded based 
on the UK Prescription Pricing Authority Dictionary [27]. The recorded information on 
diagnoses and drug use was validated and proved to be of high quality [28, 29].  
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Study population 
All patients with at least one prescription of anti-diabetic drugs (ADD) (oral non-insulin anti-
diabetic drugs (NIAD) and/or insulin) and aged 18 years or older during the period of CPRD 
data collection were included. The date of the first ADD prescription was defined as the 
index date (baseline or t0) of the start cohort. From this start cohort, all subjects with missing 
data for smoking status, a history of any cancer prior to the index date, except non-melanoma 
skin cancer, a diagnosis of gestational diabetes or secondary diabetes ever during follow-up 
were excluded. Furthermore, all ADD users with diagnoses of both type 1 and 2 diabetes, all 
ADD users with diagnoses of type 1 diabetes were excluded as were all ADD users with only 
insulin use at baseline and younger than 30 years. The full cohort was further restricted to all 
patients with at least one year without exposure to ADDs before the start of treatment (t0), 
(one year of non-use or washout prior to t0) to create the inception cohort. All study 
participants were followed up from the index date to either the end of data collection, the date 
of transfer of the patient out of the practice area, or the patient's death. 
Exposure 
Patients with type 2 diabetes were all patients with a formal diagnosis of type 2 diabetes or 
using an oral ADD at index date. The total period of follow-up for each patient was divided 
into fixed time periods of 90 days. Age was determined at the start of each interval. Sex, 
smoking status and BMI were determined at baseline. Diabetes duration was assessed 
retrospectively by estimating the time since the date of the first ADD prescription (the index 
date, t0). Diabetes control was assessed in a time-dependent manner using the most recent 
HbA1c record before the start of each time interval in the previous year.   
Current exposure to all ADD was assessed at the start of each interval in a time-dependent 
manner. Current use was defined as a prescription at the start date or in the 90 days before. 
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Current use was further stratified by type of ADD. Additional to insulin, the following classes 
of ADDs were defined: biguanides (metformin), sulfonylureas (SUs) (glibenclamide, 
gliclazide, glimepiride, glipizide, gliquidon), glinides (repaglinide), glitazones or 
thiazolidinesdiones (pioglitazone, rosiglitazon), dipeptidyl peptidase-4 inhibitors (DPP-4-
inhibitors) (saxagliptine, sitagliptine, vildagliptine). All NIADs not belonging to these 
specific categories were combined in a separate category (other ADD users). This category 
contains following groups: glinides only, glitazones only, DPP-4-inhibitors only, insulin only, 
SUs combined (not-metformin) and others including incretinemimetica (exenatide, 
liraglutide). When there was no prescription in the 90 days before the start of an interval, the 
interval was classified as past use.  
Controls were those patients who had used SU alone.  
 
Outcomes 
Patients were followed up for the occurrence of a first medical record for bladder cancer, as 
defined by Read codes in CPRD. 
 
Potential confounders 
The major covariates of interest included age, sex, smoking status and BMI. Smoking status 
was characterized at baseline as current, former, or non-smoker. Age was assessed in a time-
dependent manner. Additional covariates were retinopathy and neuropathy as a measure for 
diabetes complications, HbA1c as a measure for diabetes control and diabetes duration. 
 
Statistical analysis 
Analyses were conducted using Cox proportional hazards models. Risks were estimated for 
an inception cohort of new ADD users using a 1-year lead-in time. The full cohort was 
therefore restricted to patients starting with metformin or SU alone within the study period 
with at least one year without exposure to ADDs before the start of treatment (t0). Study 
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follow-up for endpoints begins at precisely the same time as initiation of therapy, or t0. Data 
for all patient characteristics are obtained at the time t0. 
The risk of UBC in different groups of ADD users was compared with SU only users. This 
analysis was stratified by ADD use: metformin alone (1), metformin in combination (2) with 
other ADD medication (glinides, glitazones, DPP-4-inhibitors, SUs, insulin or more than one 
combination), all metformin users (1 + 2). The estimates were adjusted for age, gender, 
smoking status and BMI and diabetes duration. The risk of UBC for patients with incident 
type 2 diabetes was further stratified by continuous duration (a gap of 30 days was allowed) 
of metformin intake and sex. A sensitivity analysis was carried out in the full cohort assessing 
the risk of UBC in the same groups of ADD users as the first analysis compared with SU only 
users. These estimates were adjusted for age, gender, smoking status, BMI and for 
retinopathy, neuropathy and HbA1c. Three more sensitivity analyses were carried out each 
time excluding cases of bladder cancer 180 days, 360 days and 720 days after ADD initiation 
(t0) to explore the effect of pre-existing cancer. 
All data management and statistical analyses were conducted using SAS 9.2 software. 
This study has been approved by the Medicines and Healthcare products Authorities’ 
Independent Scientific Advisory Committee, protocol number 13_050R. 
RESULTS 
In total, 392,544 patients aged 18 years and older, were identified with at least one 
prescription for an ADD during the period of CPRD data collection (start cohort). After 
exclusion of 1,983 patients with a diagnosis of gestational diabetes, 485 patients with 
secondary diabetes, 34,955 patients with cancer prior to index date, 13,416 patients with 
missing data for smoking status during follow up, 7,614 patients diagnosed with type 1 and 2 
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diabetes at baseline, 49,997 patients with diagnosis of type 1 diabetes and 2,376 patients with 
only insulin use at baseline and younger than 30 years, the full cohort consisted of 290,918 
participants. Limiting the full cohort to incident ADD users with a 1-year lead-in time, 
reduced the population further to 165,398 participants of which 132,960 metformin users and 
32,438 SU only users (Figure 1). 
Table 1 shows baseline characteristics of the inception cohort. SU users were older (66 year) 
at index date compared to the metformin users (58 year). Approximately 50% of the ADD 
users were non-smokers. Sixty percent of the metformin only users had a BMI of 30 or above 
in contrast with only one fourth of the control subjects. A small percentage (around 3%) of 
the ADD-users had already neuropathy and retinopathy at baseline. 
During a mean follow-up of more than five years 693 patients developed UBC, 124 of the 
control group and 461 of the all metformin users (Table 2). There was no association between 
metformin use and UBC risk (HR = 1.12 (95% CI 0.90-1.40)) compared to SU only users, 
even after adjustment for diabetes duration (HR = 1.13 (95% CI 0.90-1.40)). The results (HR 
= 1.05 (95% CI 0.89-1.24)) for ADD users in the full cohort were similar (Table 3). 
Adjustment for history of complications (neuropathy, retinopathy) and the severity of 
diabetes (HbA1c) did not alter the risk (Table 3). 
For incident metformin users, we noticed a non-significant increased risk of UBC (HR = 1.14 
(95% CI 0.88-1.48)) during the first year after the first ADD prescription, compared to 
controls, disappearing in subsequent years (Table 4). There was a not significant linear 
association between the risk of bladder cancer over time (Ptrend = 0.07). There was no 
difference in UBC risk between males and females metformin users (HR = 1.12 (95% CI 
0.86-1.47) and 0.86 (95% CI 0.52-1.42), respectively). 
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DISCUSSION 
We found no association between incident metformin users and UBC risk compared to 
incident SU users. Even if there was a pattern of decreasing risk of UBC with increasing 
duration of metformin intake, it was not statistically significant. Our results were in line with 
the findings of a similar study, the UK inception cohort study using The Health Improvement 
Network database [30]. 
We showed that the metformin users were on average younger than the SU users (58 versus 
66.8 years) and more obese (nearly 60% has a BMI above 30). These findings confirm that 
metformin is the first choice for obese type 2 diabetes patients because metformin offers 
glucose lowering with some weight loss [10, 31]. 
Although this study has many strengths, there are several limitations. The CPRD is a large 
population-based cohort representative of the total UK population. Consulting rates for 
diabetes in the CPRD have been compared with equivalent data from the 4th National 
Morbidity Survey in General Practice confirming the validity of the morbidity data in the 
CPRD [29]. Since 2004, GPs are stimulated to provide “quality care” by the Quality and 
Outcomes Framework (QOF). The UK has a National Service Framework (NSF) for Diabetes 
[32]. Guidelines to be followed by the GPs are outlined in the guideline for type 2 diabetes 
[10] of the National Institute for Health and Care Excellence (NICE). Although guidelines for 
the treatment of type 2 diabetes have changed over time, the general approach remained fairly 
consistent: blood-glucose lowering therapy is started in a step-up system if HbA1c is equal to 
or more than 6.5% after lifestyle interventions. First step is mono-therapy with metformin or 
SU. In a second step, dual and even triple therapy of NIAD which may be combined with 
insulin therapy, and ultimately insulin mono-therapy are used if HbA1c is still equal to or 
more than 6.5%. [10, 33, 34]  
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The CPRD comprises electronic medical records from British GPs. Diagnosis of bladder 
cancer depends on the registration of this diagnosis in the database by the GP and patients can 
be subject to non-adherence of their therapy. So, underestimation of bladder cancer cases is 
possible, but should be equal in both groups. Despite the fact that the CPRD contains data 
from over 10 million patients, bladder cancer patients are still limited as is the follow-up 
time. The median follow-up time of metformin only users is 4.6 years with a maximum of 7.7 
years. Diabetes patients are on metformin alone during a limited time of their disease. As 
their diabetes progresses, combination of ADDs may be necessary. 
We were able to collect a large inception cohort of type 2 diabetes patients (n=165,398) 
reducing our cohort to all new patients with a formal type 2 diabetes diagnosis or ADD use.  
All analysed patients had data on smoking status, the main confounder for bladder cancer. 
Although this cohort still contains 12,841 women with diagnosis of polycystic ovarian 
syndrome (PCOS), rare off-label indications unlikely affect pharmacological hypothesis. A 
sensitivity-analysis excluding these PCOS patients estimating the risk of bladder cancer in 
diabetes patients compared to non-diabetes controls did not alter the results in the same 
cohort of diabetes patients [6]. We preferred to use an inception cohort instead of a nested 
case-control design. While the nested case-control design allows for statistically efficient 
analysis of data from a cohort with substantial savings in cost and time especially when a lot 
of covariates are included in the model for more rare diseases in databases [35],using a new-
user design consistently avoids time-related biases as described by Suissa and Azouly [23]. 
Immortal time has been avoided by including patients as new users of metformin or SU after 
a 1-year lag period before enrolment in the inception cohort. Both drugs are first-line 
treatment for type 2 diabetes, so both groups are in the same stage of their disease avoiding 
time-lag bias by comparing first-line treatment with second- or third-line treatments. 
Metformin and SU use have been analysed in a time-dependent way. The different 
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continuous duration of metformin intake were compared to the same strata of SU only use to 
avoid time-window bias. Whereas the nested case-control approach is described by Essebag 
et al. [35] as a useful alternative for cohort analysis when studying time-dependent exposures 
compared to Cox regression including time-dependent covariates, in reality there are still 
differences. Both Azoulay et al. and Wei et al. estimated the risk of bladder cancer in patients 
with type 2 diabetes exposed to pioglitazone in the CPRD respectively conducting a nested 
case-control study and a propensity score matched cohort study and reporting respectively an 
increased risk (rate ratio =1.83 (95% CI 1.10-3.05)) and a not increased rate (HR = 1.16 (95% 
CI 0.83-1.62)).  
A possible shortcoming of this study is that we did not evaluate the exposure to metformin or 
SU by cumulative dosage. Patients with sporadic use of metformin were analysed in the first 
duration category (< 1 year), and compared to the same category of SU users. 
With this study we were able to confirm that time-related bias could be an explanation of the 
anti-cancer effect of metformin noticed in many epidemiological studies. However, there is 
still the plausibility for metformin as an anti-cancer drug in laboratory models [7] even if 
some of these experiments were done with concentrations exceeding those achieved with 
conventional doses used for diabetes treatment [36]. Furthermore, a first pilot clinical trial 
using metformin 500 mg daily in patients with endometrial cancer from diagnostic biopsy to 
surgery, presented biological evidence consistent with anti-proliferative effects of metformin 
in the clinical setting [37]. The results of similar studies done in breast cancer were 
inconsistent [36]. Nevertheless, trials using more aggressive doses of biguanides or using 
novel biguanides may be expected in the future [38]. 
We noticed a non-significantly increased risk of UBC (HR = 1.14 (95% CI 0.88-1.48)) during 
the first year after the first ADD prescription, compared to controls. A same increase in risk 
has been seen after diabetes diagnosis [6] most likely indicating the presence of detection 
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bias. The sensitivity analyses inducing a time lag period of 180, 360 or 720 days did not 
confirm the hypothesis that the increased risk detected during the first year was due to 
metformin (HR = 1.11 (95% CI 0.84-1.47) for 360 days time lag period). 
After avoiding all time-related biases, we could not detect a protective effect of metformin 
for the risk of UBC. The effect of metformin on the recurrence and progression of UBC was 
beyond the scope of this study and requires further investigation.   
 
CONCLUSION 
Metformin has no influence on the risk of UBC compared to sulfonylurea in type 2 diabetes 
patients using a new-user design.  
 
 
List of abbreviations  
UBC = urinary bladder cancer  
CPRD = Clinical Practice Research Datalink  
ADD = anti-diabetic drugs 
RCT = randomised clinical trials 
HR = hazard ratio 
GP = general practitioner 
NIAD = non-insulin anti-diabetic drug 
QOF = Quality and Outcomes Framework 
NSF = National Service Framework 
NICE = National Institute for Health and Care Excellence 
PCOS = polycystic ovarian syndrome 
 
This article is protected by copyright. All rights reserved. 
 
Contributorship statement 
ME.G. wrote the manuscript and researched data. J.D. performed the statistical analysis and 
reviewed the manuscript. F.B. and MP.Z. reviewed/edited the manuscript. F.dV. and ML.DB. 
provided the data and reviewed/edited the manuscript. 
 
Competing interests 
"All authors have completed the Unified Competing Interest form at 
http://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) 
and declare: no support from any organisation for the submitted work; no financial 
relationships with any organisations that might have an interest in the submitted work in the 
previous 3 years; no other relationships or activities that could appear to have influenced the 
submitted work" 
The research leading to the results of this study has received funding from the European 
Community’s Seventh Framework Programme (FP-7) under grant agreement number 
282526, the CARING project. The funding source had no role in study design, data 
collection, data analysis, data interpretation or writing of the report. 
 
Data sharing statement 
CPRD data is available under license with the Medicines and Healthcare products Regulatory 
Agency (MHRA) in London, UK. The datasets which have been used for this project have 
been licensed by the MHRA. Access to datasets that have been used for this study are 
available for audit purposes only, conditional upon permission by the MHRA. 
 
 
This article is protected by copyright. All rights reserved. 
REFERENCES  
1. International Diabetes Federation. IDF Diabetes Atlas, 6th edn Brussels, Belgium: 
International Diabetes Federation 2014; http://www.idf.org/diabetesatlas. 
2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, 
Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC 
CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer 2013; 
Available from: http://globocan.iarc.fr. 
3. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a 
meta-analysis. Diabetologia 2006; 49: 2819-23. 
4. Zhu Z, Zhang X, Shen Z, Zhong S, Wang X, Lu Y, Xu C. Diabetes mellitus and risk of 
bladder cancer: a meta-analysis of cohort studies. PloS one 2013; 8: e56662. 
5. Xu X, Wu J, Mao Y, Zhu Y, Hu Z, Xu X, Lin Y, Chen H, Zheng X, Qin J, Xie L. Diabetes 
mellitus and risk of bladder cancer: a meta-analysis of cohort studies. PloS one 2013; 8: e58079. 
6. Goossens ME, Zeegers MP, Bazelier MT, De Bruin ML, Buntinx F, de Vries F. Risk of 
bladder cancer in patients with diabetes: a retrospective cohort study. BMJ Open 2015; 5: e007470. 
7. Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. Annals 
of translational medicine 2014; 2: 57. 
8. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. 
https://clinicaltrials.gov. 
9. International Diabetes Federation. IDF Global Guideline for type 2 Diabetes 2012 Brussels, 
Belgium: International Diabetes Federation 2012; http://www.idf.org/diabetesatlas. 
10. Type 2 diabetes | Guidance and guidelines | NICE. http://wwwniceorguk/guidance/cg87 
2009. 
11. Malek M, Aghili R, Emami Z, Khamseh ME. Risk of cancer in diabetes: the effect of 
metformin. ISRN endocrinology 2013; 2013: 636927. 
12. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin 
therapy and risk of cancer in patients with type 2 diabetes: systematic review. PloS one 2013; 8: 
e71583. 
13. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of 
metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. 
Diabetes care 2009; 32: 1620-5. 
14. Ngwana G, Aerts M, Truyers C, Mathieu C, Bartholomeeusen S, Wami W, Buntinx F. 
Relation between diabetes, metformin treatment and the occurrence of malignancies in a Belgian 
primary care setting. Diabetes research and clinical practice 2012; 97: 331-6. 
15. Tseng CH. Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 
diabetes. Acta diabetologica 2014; 51: 295-303. 
16. Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit in cancer 
patients with concurrent type 2 diabetes: a systematic review and meta-analysis. The oncologist 2013; 
18: 1248-55. 
17. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for 
patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes care 2006; 29: 254-8. 
18. Zhang T, Guo P, Zhang Y, Xiong H, Yu X, Xu S, Wang X, He D, Jin X. The antidiabetic 
drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo. International 
journal of molecular sciences 2013; 14: 24603-18. 
19. Zhang T, Wang X, He D, Jin X, Guo P. Metformin sensitizes human bladder cancer cells to 
TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP. Anti-cancer 
drugs 2014. 
20. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, Lotan Y, Karakiewicz PI, 
Fajkovic H, Babjuk M, Kautzky-Willer A, Bachmann A, Scherr DS, Shariat SF. Association of 
diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive 
bladder cancer. BJU international 2013; 112: 1105-12. 
 
This article is protected by copyright. All rights reserved. 
21. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, Lotan Y, Karakiewicz PI, 
Sun M, Fajkovic H, Babjuk M, Bachmann A, Scherr DS, Shariat SF. Effect of diabetes mellitus and 
metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial 
carcinoma. Urologic oncology 2014; 32: 49 e7-14. 
22. Stevens RJ, Ali R, Bankhead CR, Bethel MA, Cairns BJ, Camisasca RP, Crowe FL, Farmer 
AJ, Harrison S, Hirst JA, Home P, Kahn SE, McLellan JH, Perera R, Pluddemann A, Ramachandran 
A, Roberts NW, Rose PW, Schweizer A, Viberti G, Holman RR. Cancer outcomes and all-cause 
mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of 
randomised clinical trials. Diabetologia 2012; 55: 2593-603. 
23. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational 
studies. Diabetes care 2012; 35: 2665-73. 
24. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. American 
journal of epidemiology 2003; 158: 915-20. 
25. Vandenbroucke JP. The HRT controversy: observational studies and RCTs fall in line. Lancet 
2009; 373: 1233-5. 
26. Robinson D, Schulz E, Brown P, Price C. Updating the Read Codes: user-interactive 
maintenance of a dynamic clinical vocabulary. Journal of the American Medical Informatics 
Association : JAMIA 1997; 4: 465-72. 
27. NHS. Prescription Services BNF Classification and Pseudo Classification used by the NHS 
Prescription Services. Incorporating changes up to and including BNF Number 66 2013. 
28. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of 
diagnoses in the General Practice Research Database: a systematic review. British journal of clinical 
pharmacology 2010; 69: 4-14. 
29. Hollowell J. The General Practice Research Database: quality of morbidity data. Population 
trends 1997: 36-40. 
30. Mamtani R, Pfanzelter N, Haynes K, Finkelman BS, Wang X, Keefe SM, Haas NB, Vaughn 
DJ, Lewis JD. Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or 
sulfonylureas. Diabetes care 2014; 37: 1910-7. 
31. Zhao Q, Marcy TR. Incretin-based therapy compared with non-insulin alternatives in elderly 
patients with type 2 diabetes. The Consultant pharmacist : the journal of the American Society of 
Consultant Pharmacists 2013; 28: 515-8. 
32. National Service Framework for Diabetes. Department of Health 2001. 
33. International Diabetes Federation. IDF Diabetes Atlas, 6th edn Brussels, Belgium: 
International Diabetes Federation 2013; http://www.idf.org/diabetesatlas. 
34. Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. 
Achievements and future developments. Drugs 1997; 54: 355-68. 
35. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and 
survival analysis methodologies for analysis of time-dependent exposure. BMC medical research 
methodology 2005; 5: 5. 
36. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the 
beginning. Cancer discovery 2012; 2: 778-90. 
37. Laskov I, Drudi L, Beauchamp MC, Yasmeen A, Ferenczy A, Pollak M, Gotlieb WH. Anti-
diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial 
cancer. Gynecologic oncology 2014; 134: 607-14. 
38. Pollak M. Metformin's potential in oncology. Clinical advances in hematology & oncology : 
H&O 2013; 11: 594-5. 
 
 
This article is protected by copyright. All rights reserved. 
 
 
 
This article is protected by copyright. All rights reserved. 
 
Table 1. Baseline characteristics of incident ADD users (inception cohort) 
 
Sulfonylurea (SU) (a) only 
users 
Metformin only users  
Characteristics n=32,438 (%) n = 132,960 (%) 
Follow-up time (years) 
  Mean (SD) 7.6 (5.2) 5.3 (3.7) 
  Median (IQR) 7.0 (3.0-11.6) 4.6 (2.2-7.7) 
Sex 
      Female 13817 (42.6) 63709 (47.9) 
  Male 18621 (57.4) 69251 (52.1) 
Age at index date (years) 
      Mean (SD) 66.0 (13.2) 58.3 (14.8) 
  Median 67 
 
60 
   By category 
       18-29 157 (0.5) 5756 (4.3) 
   30-39 849 (2.6) 9825 (7.4) 
   40-49 2828 (8.7) 18976 (14.3) 
   50-59 5920 (18.3) 31562 (23.7) 
   60-69 8777 (27.1) 34996 (26.3) 
   70-79 8900 (27.4) 23745 (17.9) 
   80+ 5007 (15.4) 8100 (6.1) 
Smoking status 
       Never smoker 16615 (51.2) 63371 (47.7) 
   Current smoker 6248 (19.3) 25146 (18.9) 
   Former smoker 9575 (29.5) 44443 (33.4) 
Body mass index 
       <20 kg/m2 1054 (3.2) 921 (0.7) 
   20-24.9 kg/m2 8768 (27.0) 11197 (8.4) 
   25-39.9 kg/m2 12718 (39.2) 39402 (29.6) 
  >=30 kg/m2 8512 (26.2) 79758 (60.0) 
  Unknown 1386 (4.3) 1682 (1.3) 
Hba1c on index date (mean (SD)) 9.2 (2.1) 8.5 (1.8) 
History of complications 
    
  Neuropathy 829 (2.6) 4574 (3.4) 
  Retinopathy 953 (2.9) 4551 (3.4) 
Incident = all index patients are included after one year lead-in time  
without anti-diabetic drugs (ADD) prescription; SD = standard deviation; IQR = interquartile range 
(a) Glibenclamide, gliclazide, glimepiride, glipizide, gliquidon 
Due to the large sample sizes, all analyses of baseline characteristics are statistically significant 
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